Stockscreener 앱 받기
64.78
11.20%
6.525
시간 외 거래:
67.87
3.095
+4.78%
전일 마감가:
$58.25
열려 있는:
$60.07
하루 거래량:
894.07K
Relative Volume:
3.57
시가총액:
$1.93B
수익:
-
순이익/손실:
$-91.00M
주가수익비율:
-16.36
EPS:
-3.9598
순현금흐름:
$-74.38M
1주 성능:
+41.12%
1개월 성능:
+29.73%
6개월 성능:
+117.44%
1년 성능:
+33.06%
1일 변동 폭
$57.91
$65.25
1주일 범위
$44.81
$65.25
52주 변동 폭
$25.60
$77.60
Disc Medicine Inc Stock (IRON) Company Profile
명칭
Disc Medicine Inc
전화
(617) 674-9274
주소
321 ARSENAL STREET, SUITE 101, WATERTOWN
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-22 | 개시 | Wells Fargo | Overweight |
| 2024-04-01 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | 개시 | H.C. Wainwright | Buy |
| 2023-05-17 | 개시 | Raymond James | Outperform |
| 2023-04-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-21 | 개시 | Stifel | Buy |
| 2023-04-20 | 개시 | Morgan Stanley | Overweight |
| 2023-03-23 | 개시 | BMO Capital Markets | Outperform |
| 2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Disc Medicine Inc 주식(IRON)의 최신 뉴스
Disc Medicine (NASDAQ:IRON) Stock Price Up 7%Here's Why - MarketBeat
Disc Medicine (NASDAQ:IRON) Earns Buy Rating from HC Wainwright - MarketBeat
Scotiabank upgrades Disc Medicine shares target on trial update By Investing.com - Investing.com UK
Disc Medicine Announces Multiple Presentations Across - GlobeNewswire
Disc Medicine to Present Complete DISC-0974 Trial Data, Portfolio Updates at ASH 2024 | IRON Stock News - StockTitan
Disc Medicine (NASDAQ:IRON) Upgraded to Overweight at Morgan Stanley - MarketBeat
Wedbush Reaffirms Outperform Rating for Disc Medicine (NASDAQ:IRON) - MarketBeat
Disc over the moon as FDA urges Apollo bid with bitopertin in EPP - BioWorld Online
FDA aligns with Disc Medicine on EPP treatment study By Investing.com - Investing.com Canada
Disc Medicine stock rallies 26% on FDA update for bitopertin (update) - Seeking Alpha
Disc Medicine Shares Rise After Positive Feedback From FDA - MarketWatch
Disc Medicine (NASDAQ:IRON) Shares Gap UpShould You Buy? - MarketBeat
Disc Medicine leaps as it gets positive FDA feedback - The Pharma Letter
Raymond James increases Disc Medicine shares to Strong Buy on new drug - Investing.com UK
Disc Medicine (NASDAQ:IRON) Rating Increased to Strong-Buy at Raymond James - MarketBeat
FDA aligns with Disc Medicine on EPP treatment study - Investing.com
Disc Medicine Gains FDA Support for Bitopertin Trial - TipRanks
Disc Medicine Announces Successful End of Phase 2 Meeting - GlobeNewswire
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval - StockTitan
(IRON) Technical Data - Stock Traders Daily
Disc Medicine to Host Conference Call on End of Phase 2 FDA - GlobeNewswire
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) - StockTitan
Disc Medicine, Inc. (NASDAQ:IRON) Short Interest Update - Defense World
Disc Medicine, Inc. (NASDAQ:IRON) Short Interest Down 6.9% in October - MarketBeat
Disc Medicine’s (IRON) “Buy” Rating Reiterated at HC Wainwright - Defense World
Recent Investment Analysts’ Ratings Updates for Disc Medicine (IRON) - Defense World
Disc Medicine's SWOT analysis: promising pipeline drives stock outlook - Investing.com India
Disc Medicine's (IRON) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Disc Medicine retains stock target, buy rating with positive CKD study data - Investing.com UK
Disc Medicine Presents Positive Data from SAD Cohorts of a - GlobeNewswire
Disc Medicine Reports Progress in Anemia Treatment Study By Investing.com - Investing.com Australia
Disc Medicine Reports Progress in Anemia Treatment Study - Investing.com
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week - The Manila Times
Disc Medicine's SWOT analysis: stock poised for growth amid clinical progress - Investing.com Australia
Disc Medicine's SWOT analysis: stock poised for growth amid clinical progress By Investing.com - Investing.com South Africa
Jefferies bullish on Disc Medicine, calls bitopertin a blockbuster in the making - Investing.com Canada
Disc Medicine stock draws but at Jefferies (IRON:NASDAQ) - Seeking Alpha
Disc Medicine appoints new chief technical officer - Investing.com
Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer - The Manila Times
Disc Medicine (NASDAQ:IRON) Now Covered by Analysts at Jefferies Financial Group - MarketBeat
How To Trade (IRON) - Stock Traders Daily
Sanctuary Advisors LLC Takes $68,000 Position in TCW Strategic Income Fund, Inc. (NYSE:TSI) - Defense World
Disc Medicine, Inc. (NASDAQ:IRON) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
DocuSign (NASDAQ:DOCU) & Freshworks (NASDAQ:FRSH) Critical Review - Defense World
Cantor Fitzgerald Reiterates Overweight Rating for Disc Medicine (NASDAQ:IRON) - Defense World
Scotiabank Begins Coverage on Disc Medicine (NASDAQ:IRON) - MarketBeat
Tax incentives announced for life science companies in Mass. - WWLP.com
Cantor Fitzgerald Reiterates "Overweight" Rating for Disc Medicine (NASDAQ:IRON) - MarketBeat
Degenerative Disc Disease Treatment Market Growth Analysis with Investment Opportunities For 2024-2033 - EIN News
Marshall Wace LLP Sells 2,179 Shares of Twin Disc, Incorporated (NASDAQ:TWIN) - Defense World
The Manufacturers Life Insurance Company Grows Stake in Disc Medicine, Inc. (NASDAQ:IRON) - Defense World
Disc Medicine Inc (IRON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):